Tytuł pozycji:
N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with hybrid structure as a candidate for a broad-spectrum antiepileptic drug
- Tytuł:
-
N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with hybrid structure as a candidate for a broad-spectrum antiepileptic drug
- Autorzy:
-
Łuszczki, Jarogniew Jacek
Abram, Michał
Lubelska, Annamaria
Kamiński, Krzysztof
Rapacz, Anna
Gaweł, Kinga
Andres-Mach, Marta
Jakubiec, Marcin
Nieoczym, Dorota
Esguerra, Camila V.
Latacz, Gniewomir
Zagaja, Mirosław
Szewczyk, Aleksandra
Wlaź, Piotr
Socała, Katarzyna
Pieróg, Mateusz
Szulczyk, Bartłomiej
- Data publikacji:
-
2020
- Słowa kluczowe:
-
ADME-Tox properties
isobolographic studies
electrophysiology
drug-resistant epilepsy
PTZ-kindling model of epilepsy
zebrafish
- Język:
-
angielski
- ISBN, ISSN:
-
19337213
- Prawa:
-
Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa
http://creativecommons.org/licenses/by/4.0/legalcode.pl
- Linki:
-
https://link.springer.com/article/10.1007/s13311-019-00773-w  Link otwiera się w nowym oknie
- Dostawca treści:
-
Repozytorium Uniwersytetu Jagiellońskiego
-
In our recent studies, we identified compound N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) as a broad-spectrum hybrid
anticonvulsant which showed potent protection across the most important animal acute seizure models such as the maximal electroshock
(MES) test, the subcutaneous pentylenetetrazole (s.c. PTZ) test, and the 6-Hz (32 mA) test in mice. Therefore, AS-1 may be
recognized as a candidate for new anticonvulsant effective in different types of human epilepsy with a favorable safety margin profile
determined in the rotarod test in mice. In the aim of further pharmacological evaluation of AS-1, in the current study, we examined its
activity in the 6-Hz (44 mA) test, which is known as the model of drug-resistant epilepsy. Furthermore, we determined also the
antiseizure activity in the kindling model of epilepsy induced by repeated injection of pentylenetetrazole (PTZ) in mice. As a result,
AS-1 revealed relatively potent protection in the 6-Hz (44 mA) test, as well as delayed the progression of kindling induced by repeated
injection of PTZ in mice at doses of 15 mg/kg, 30 mg/kg, and 60 mg/kg. Importantly, the isobolographic analysis showed that a
combination of AS-1 and valproic acid (VPA) at the fixed ratio of 1:1 displayed a supra-additive (synergistic) interaction against PTZinduced
seizures inmice. Thus, AS-1may be potentially used in an add-on therapy with VPA. Moreover, incubation of zebrafish larvae
with AS-1 substantially decreased the number, cumulative but not the mean duration of epileptiform-like events in electroencephalographic
assay. Finally, the in vitro ADME-Tox studies revealed that AS-1 is characterized by a very good permeability in the parallel
artificial membrane permeability assay test, excellent metabolic stability on human liver microsomes (HLMs), no significant influence
on CYP3A4/CYP2D6 activity, and moderate inhibition of CYP2C9 in a concentration of 10 $\mu$M, as well as no hepatotoxic properties in
HepG2 cells (concentration of 10 $\mu$M).